Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.66 |
| ▸ | MC4R | P32245 | 1/20 | 0.55 |
| ▸ | CHKA | P35790 | 10/20 | 0.54 |
| ▸ | CA2 | P00918 | 1/20 | 0.54 |
| ▸ | NCF1 | P14598 | 1/20 | 0.54 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28047802 | 0.89 | LMNA (0.54) | LMNAMC4RCHKACA2NCF1 | |
| SCHEMBL22169184 | 0.86 | LMNA (0.62) | LMNAMC4RCHKACA2NCF1 | |
| SCHEMBL16178546 | 0.86 | LMNA (0.62) | LMNAMC4RCHKACA2NCF1 | |
| SCHEMBL16054965 | 0.86 | ALDH1A1 (0.58) | LMNAALDH1A1KDM4EMAPTNPC1 | |
| SCHEMBL16053997 | 0.85 | LMNA (0.49) | LMNAMC4RCHKACA2NCF1 | |
| SCHEMBL22164008 | 0.85 | LMNA (0.65) | LMNAMC4RCHKACA2NCF1 | |
| SCHEMBL22164021 | 0.85 | LMNA (0.60) | LMNAMC4RCHKACA2NCF1 | |
| SCHEMBL28366319 | 0.83 | ALDH1A1 (0.60) | NCF1PRMT6ALDH1A1KDM4E | |
| SCHEMBL29959053 | 0.82 | LMNA (0.57) | LMNAMC4RCHKACA2NCF1 | |
| SCHEMBL520829 | 0.82 | LMNA (0.57) | LMNAMC4RCHKACA2NCF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116217551-B | Substituted indazole or azaindazole compounds and application thereof | 河南中医药大学 | 2024-07-30 | — | — | CN | disclosed |
| CN-112047932-B | Pyrazole spleen tyrosine kinase inhibitor and preparation method and application thereof | 中国药科大学 | 2022-11-08 | — | — | CN | disclosed |
| EP-3186247-B1 | PROTEIN KINASE INHIBITORS | ASTAR BIOTECH LLC (US) | 2021-03-03 | — | — | EP | disclosed |
| EP-3186247-B1 | PROTEIN KINASE INHIBITORS | ASTAR BIOTECH LLC (US) | 2021-03-03 | — | — | EP | disclosed |
| CN-112047932-A | Pyrazole spleen tyrosine kinase inhibitor and preparation method and application thereof | 中国药科大学 | 2020-12-08 | — | — | CN | disclosed |
| EP-2880038-B1 | PROTEIN KINASE INHIBITORS | ASTAR BIOTECH LLC (US) | 2018-05-16 | — | — | EP | disclosed |
| EP-2880038-B1 | PROTEIN KINASE INHIBITORS | ASTAR BIOTECH LLC (US) | 2018-05-16 | — | — | EP | disclosed |
| US-9776988-B2 | Pyrazolylbenzo[d]imidazole derivatives | CELON PHARMA S.A. (PL) | 2017-10-03 | — | — | US | disclosed |
| US-9776988-B2 | Pyrazolylbenzo[d]imidazole derivatives | CELON PHARMA S.A. (PL) | 2017-10-03 | — | — | US | disclosed |
| US-9776988-B2 | Pyrazolylbenzo[d]imidazole derivatives | CELON PHARMA S.A. (PL) | 2017-10-03 | — | — | US | disclosed |
| CN-101379058-A | Pyrazole compounds that modulate the activity of CDK, GSK and aurora kinases | ASTEX THERAPEUTICS LTD (GB) | 2009-03-04 | — | — | CN | disclosed |
| EP-1968579-A1 | PHARMACEUTICAL COMPOUNDS | Astex Therapeutics Limited (GB) | 2008-09-17 | — | — | EP | disclosed |
| US-20080132495-A1 | Pyrazole Compounds that Modulate the Activity of Cdk, Gsk and Aurora Kinases | ASTEX THERAPEUTICS LIMITED (GB) | 2008-06-05 | — | — | US | disclosed |
| US-20080132495-A1 | Pyrazole Compounds that Modulate the Activity of Cdk, Gsk and Aurora Kinases | ASTEX THERAPEUTICS LIMITED (GB) | 2008-06-05 | — | — | US | disclosed |
| US-20080132495-A1 | Pyrazole Compounds that Modulate the Activity of Cdk, Gsk and Aurora Kinases | ASTEX THERAPEUTICS LIMITED (GB) | 2008-06-05 | — | — | US | disclosed |
| EP-1833819-A1 | PYRAZOLE COMPOUNDS THAT MODULATE THE ACTIVITY OF CDK, GSK AND AURORA KINASES | Astex Therapeutics Limited (GB) | 2007-09-19 | — | — | EP | disclosed |
| WO-2007077435-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2007-07-12 | — | — | WO | disclosed |
| WO-2007077435-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2007-07-12 | — | — | WO | disclosed |
| US-20070004635-A1 | Method of treating interferon non-responders using HCV protease inhibitor | SCHERING CORPORATION | 2007-01-04 | — | — | US | disclosed |
| WO-2006070195-A1 | PYRAZOLE COMPOUNDS THAT MODULATE THE ACTIVITY OF CDK, GSK AND AURORA KINASES | ASTEX THERAPEUTICS LIMITED (GB) | 2006-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004635-A1 | Method of treating interferon non-responders using HCV protease inhibitor | IFNAR1, IFNG, IRF3 | LMNA 1935/4885MC4R 4577/4885CHKA 1977/4885 |
| US-20080132495-A1 | Pyrazole Compounds that Modulate the Activity of Cdk, Gsk and Aurora Kinases | CDK3, CDK1, AURKA | LMNA 634/4885MC4R 1888/4885CHKA 223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.